Loading…
Based on limited metadata, the FDA issued a Warning Letter to Malladi Drugs & Pharmaceuticals Ltd., a pharmaceutical manufacturer, on March 9, 2018. Without access to the full letter text or subject line details, the specific violations cannot be determined with certainty. The warning appears to relate to pharmaceutical manufacturing or operations, though the exact product category and issuing FDA office are not specified in the available metadata. To understand the full scope and nature of the regulatory concerns, the complete Warning Letter would need to be reviewed.